Medical Transcription Billing (NASDAQ:MTBC) vs. SS&C Technologies (NASDAQ:SSNC) Financial Comparison

Share on StockTwits

Medical Transcription Billing (NASDAQ:MTBC) and SS&C Technologies (NASDAQ:SSNC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and target prices for Medical Transcription Billing and SS&C Technologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medical Transcription Billing 0 0 2 0 3.00
SS&C Technologies 0 1 10 2 3.08

Medical Transcription Billing currently has a consensus target price of $6.00, suggesting a potential upside of 28.21%. SS&C Technologies has a consensus target price of $70.54, suggesting a potential upside of 19.05%. Given Medical Transcription Billing’s higher possible upside, equities analysts plainly believe Medical Transcription Billing is more favorable than SS&C Technologies.

Insider and Institutional Ownership

6.5% of Medical Transcription Billing shares are held by institutional investors. Comparatively, 82.7% of SS&C Technologies shares are held by institutional investors. 50.5% of Medical Transcription Billing shares are held by insiders. Comparatively, 14.5% of SS&C Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Medical Transcription Billing and SS&C Technologies’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Medical Transcription Billing $50.55 million 1.11 -$2.14 million ($0.59) -7.93
SS&C Technologies $3.42 billion 4.38 $103.20 million $2.62 22.61

SS&C Technologies has higher revenue and earnings than Medical Transcription Billing. Medical Transcription Billing is trading at a lower price-to-earnings ratio than SS&C Technologies, indicating that it is currently the more affordable of the two stocks.

Dividends

SS&C Technologies pays an annual dividend of $0.40 per share and has a dividend yield of 0.7%. Medical Transcription Billing does not pay a dividend. SS&C Technologies pays out 15.3% of its earnings in the form of a dividend. SS&C Technologies has increased its dividend for 4 consecutive years.

Volatility and Risk

Medical Transcription Billing has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, SS&C Technologies has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.

Profitability

This table compares Medical Transcription Billing and SS&C Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Medical Transcription Billing -6.22% -10.79% -8.52%
SS&C Technologies 3.20% 17.19% 5.14%

Summary

SS&C Technologies beats Medical Transcription Billing on 14 of the 18 factors compared between the two stocks.

About Medical Transcription Billing

Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company’s offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform. PracticePro includes practice management software and related tools, which facilitate the day-to-day operation of a medical practice; electronic health records (EHR), which allow its customers to qualify for government incentives; revenue cycle management (RCM) services, which include medical billing, analytics and related services, and mobile Health (mHealth) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services. The Company offers a clearinghouse service, which allows clients to track claim status.

About SS&C Technologies

SS&C Technologies Holdings, Inc. provides software products and software-enabled services to financial services and healthcare industries in the United States, Canada, rest of the Americas, Europe, the Asia Pacific, and Japan. The company's products and services allow its clients to automate and integrate front-office functions, such as trading and modeling; middle-office functions, including portfolio management and reporting; and back-office functions comprising accounting, transfer agency, compliance, regulatory services, performance measurement, reconciliation, reporting, processing, and clearing. It provides solutions to clients in institutional asset and wealth management, alternative investment management, brokerage, retirement, financial advisory, and financial institutions vertical markets, commercial lenders, real estate investment trusts, corporate treasury groups, insurance companies, pension funds, municipal finance groups, and real estate property managers. The company also offers health care solutions, such as claims adjudication, benefit management, care management, and business intelligence services to health care industry that include pharmacy, healthcare administration, and health optimization solutions, as well as provides professional and products support services. SS&C Technologies Holdings, Inc. was founded in 1986 and is headquartered in Windsor, Connecticut.

Receive News & Ratings for Medical Transcription Billing Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Transcription Billing and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Berenberg Bank Reiterates “€16.00” Price Target for Hellofresh
Berenberg Bank Reiterates “€16.00” Price Target for Hellofresh
Indus  PT Set at €56.00 by Warburg Research
Indus PT Set at €56.00 by Warburg Research
Independent Research Reiterates €5.30 Price Target for Kloeckner & Co SE
Independent Research Reiterates €5.30 Price Target for Kloeckner & Co SE
Independent Research Analysts Give MorphoSys  a €116.00 Price Target
Independent Research Analysts Give MorphoSys a €116.00 Price Target
Nemetschek  PT Set at €50.00 by Berenberg Bank
Nemetschek PT Set at €50.00 by Berenberg Bank
Analysts’ Downgrades for August, 16th
Analysts’ Downgrades for August, 16th


© 2006-2019 Ticker Report